-
公开(公告)号：US10028961B2
公开(公告)日：2018-07-24
申请号：US15093345
申请日：2016-04-07
发明人： Zenon D. Konteatis , Janeta Popovici-Muller , Jeremy M. Travins , Robert Zahler , Zhenwei Cai , Ding Zhou
IPC分类号： C07D401/04 , C07D403/04 , A61K31/506 , A61P35/00 , A61K31/53 , C07D417/04 , A61K45/06 , C07D251/18 , C07D401/14 , C07D405/14 , C07D405/12 , C07D413/04 , C07D417/14
CPC分类号： A61K31/53 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
-
公开(公告)号：US20230365592A1
公开(公告)日：2023-11-16
申请号：US18114635
申请日：2023-02-27
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein.
These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.-
公开(公告)号：US10946023B2
公开(公告)日：2021-03-16
申请号：US16167725
申请日：2018-10-23
发明人： Zenon D. Konteatis , Janeta Popovici-Muller , Jeremy Travins , Robert Zahler , Zhenwei Cai , Ding Zhou
IPC分类号： C07D251/48 , C07D251/10 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , A61K31/53 , A61K45/06 , C07D251/18 , A61K31/506 , A61K31/5377
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
-
公开(公告)号：US20180079753A1
公开(公告)日：2018-03-22
申请号：US15691408
申请日：2017-08-30
发明人： Zenon D. Konteatis , Zhihua Sui , Jeremy M. Travins , Zhixiong Ye
IPC分类号： C07D487/04 , C07D519/00 , C07F9/6561
CPC分类号： C07D487/04 , C07D519/00 , C07F9/6561
摘要： The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
-
公开(公告)号：US20160220572A1
公开(公告)日：2016-08-04
申请号：US15093345
申请日：2016-04-07
发明人： Zenon D. Konteatis , Janeta Popovici-Muller , Jeremy M. Travins , Robert Zahler , Zhenwei Cai , Ding Zhou
IPC分类号： A61K31/53 , C07D401/04 , C07D251/18 , C07D405/14 , A61K31/506 , C07D405/12 , C07D403/04 , C07D417/04 , C07D413/04 , C07D417/14 , A61K45/06 , C07D401/14
CPC分类号： A61K31/53 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
-
公开(公告)号：US20230339980A1
公开(公告)日：2023-10-26
申请号：US18214831
申请日：2023-06-27
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein.
These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.-
公开(公告)号：US10800782B2
公开(公告)日：2020-10-13
申请号：US16219735
申请日：2018-12-13
发明人： Zenon D. Konteatis , Zhihua Sui , Jeremy M. Travins , Zhixiong Ye
IPC分类号： C07D487/04 , C07D519/00 , C07F9/6561
摘要： The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
-
公开(公告)号：US20190117661A1
公开(公告)日：2019-04-25
申请号：US16167725
申请日：2018-10-23
发明人： Zenon D. Konteatis , Janeta Popovici-Muller , Jeremy Travins , Robert Zahler , Zhenwei Cai , Ding Zhou
IPC分类号： A61K31/53 , C07D401/04 , C07D417/14 , C07D403/04 , C07D405/12 , C07D405/14 , C07D401/14 , C07D251/18 , A61K45/06 , C07D417/04 , C07D413/14 , C07D403/10 , A61K31/5377 , C07D251/48 , A61K31/506 , C07D413/04
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
-
公开(公告)号：US09579324B2
公开(公告)日：2017-02-28
申请号：US14328885
申请日：2014-07-11
发明人： Zenon D. Konteatis , Janeta Popovici-Muller , Jeremy M. Travins , Robert Zahler , Zhenwei Cai , Ding Zhou
IPC分类号： C07D251/48 , C07D401/04 , C07D401/14 , C07D403/04 , A61K31/53 , A61P35/00 , C07D417/04 , A61K45/06 , C07D251/18 , C07D405/14 , C07D405/12 , C07D413/04 , A61K31/506 , C07D417/14
CPC分类号： A61K31/53 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
摘要翻译： 提供的是用于治疗癌症的化合物和治疗癌症的方法，包括向有需要的受试者施用本文所述的化合物。
-
10.发明授权公开(公告)号：US10376510B2
公开(公告)日：2019-08-13
申请号：US14903947
申请日：2014-07-10
IPC分类号： A61K31/506 , C07D239/48 , A61K31/505 , C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D493/08 , A61K45/06
摘要： Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.032 秒)
